Key facts
- Ruijing Bio’s last known valuation is $109.1M (Apr 2022).
- It has raised $44.0M; the latest was Later Stage VC ($13.7M) in May 2025.
- Notable investors include ZhenFund, Guotai Junan Innovation Investment, Shenzhen Yifeng Investment Management Enterprise, Prosperico Ventures, Rencent Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Ruijing Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Ruijing Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ruijing Bio
Developer of molecular diagnosis technology designed for precision cancer medicine. The company offers digital PCR thermal cycler and Next Generation Sequencing machines for applications in thyroid cancer detection, thereby enabling medical professionals to deliver more accurate and earlier diagnoses to patients.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2017
- Employees
- 200
- Website
- rigen-bio.com/
- Ownership
- Privately Held (backing)
Ruijing Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ruijing Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ruijing Bio in its N-PORT filings yet. We sweep new filings monthly.